DEPARTMENT OF PHARMACY, AL-MAARIF UNIVERSITY COLLEGE, AL-ANBAR, IRAQ.
Wiad Lek. 2024;77(4):828-833. doi: 10.36740/WLek202404131.
Aim: The main goal is to assess the levels of comorbid diseases and examine the changes in D-dimer in hospitalized patients before and following SC enoxaparin medication.
Material and Methods: At the Al-Yarmouk Teaching Hospital in Baghdad, Iraq, from October 2022 to May 2023, 86 patients who were hospitalized and had severe to critical COVID-19 infections provided data for a retrospective analysis.
Results: The medical records of all COVID-19 patients who were hospitalized and whose D-dimer level was greater than 0.5 mg/l and who were given enoxaparin (40 mg subcutaneously) were reviewed with the requisite authorization from the relevant authorities. The D-dimer level was assessed following therapy on the day of admission and day five after commencing enoxaparin. An examination of 86 case records revealed that persons with COVID-19 had significantly decreased D-dimer levels after taking subcutaneous enoxaparin (p-value<0.0001). The comorbidities (diabetes mellitus, hypertension) of patients who received the drug were compared.
Conclusions: Enoxaparin and other anticoagulants were utilized to treat the coagulopathy brought on by COVID-19. Low molecular weight heparin enoxaparin has demonstrated positive outcomes in the management of VTE. A decrease in D-dimer level is anticipated when COVID-19 patients are treated with subcutaneous enoxaparin, partly because decreased coagulation results in lower fibrin formation.
目的：主要目标是评估合并症的水平，并检查住院患者在使用 SC 依诺肝素前后 D-二聚体的变化。
材料和方法：在伊拉克巴格达的 Al-Yarmouk 教学医院，2022 年 10 月至 2023 年 5 月，对 86 名患有严重至危重新冠肺炎感染并住院的患者进行了回顾性分析。
结果：对所有 COVID-19 住院患者的病历进行了回顾，这些患者的 D-二聚体水平大于 0.5 毫克/升，并接受了依诺肝素（40 毫克皮下注射）治疗，同时获得了相关当局的必要授权。在入院当天和开始使用依诺肝素后第五天评估了 D-二聚体水平。对 86 份病历的检查显示，COVID-19 患者在接受皮下依诺肝素治疗后 D-二聚体水平显著降低（p 值<0.0001）。比较了接受药物治疗的患者的合并症（糖尿病、高血压）。
结论：依诺肝素和其他抗凝剂被用于治疗 COVID-19 引起的凝血障碍。低分子量肝素依诺肝素在治疗 VTE 方面取得了积极的结果。当 COVID-19 患者接受皮下依诺肝素治疗时，预计 D-二聚体水平会降低，部分原因是凝血减少导致纤维蛋白形成减少。
